Congratulations to Our New Board Members!
These incoming BOD members take office June 1. - April 18, 2025
The incoming members of the Board of Directors will assume their roles on June 1, 2025.
The American Society of Gene & Cell Therapy (ASGCT) is pleased to announce the election of five new members of the Board of Directors, all of whom will take office on June 1, 2025. The distinguished additions to the Society's leadership team are leading experts and pioneers in the field dedicated to advancing cell and gene therapies.
Barry Byrne, MD, PhD, of the University of Florida, will serve as Vice President, ascending through the presidential succession before serving as ASGCT President in 2027-2028. Joining him are Marcela Maus, MD, PhD, of Massachusetts General Hospital; Laura Sepp-Lorenzino, PhD, of Intellia Therapeutics; Steven Gray, PhD, of UT Southwestern Medical Center; and Allison Bradbury, PhD, of Nationwide Children's Hospital.
Vice President (Term of Office: 2025-2028)
Barry Byrne, MD, PhD
University of Florida
Secretary (2025-2028)
Marcela Maus, MD, PhD
Massachusetts General Hospital
At-Large Director (2025-2028)
Laura Sepp-Lorenzino, PhD
Intellia Therapeutics
At-Large Director (2025-2028)
Steven Gray, PhD
UT Southwestern Medical Center
At-Large Director (2025-2028)
Membership Council Chair
Allison Bradbury, PhD
Nationwide Children’s Hospital
"We are privileged to welcome these distinguished leaders who will contribute exceptional knowledge and expertise to our Society," said David Barrett, JD, CEO of ASGCT. "Their leadership will be vital as we advance innovation and breakthroughs in gene and cell therapies, ultimately enhancing patient care across the globe."
The new Board members will hit the ground running at the ASGCT 28th Annual Meeting, taking place May 13-17 in New Orleans and online. The premier event in cell and gene therapy, the Annual Meeting gathers researchers, clinicians, bio-industry developers, patient advocates, and more to explore the latest discoveries and discuss key challenges in translating gene and cell therapy research into clinical practice.
Meeting registrants can look forward to an extensive scientific program featuring nearly 2,500 invited speakers, oral presentations, and posters across the world of CGT. All in-person and virtual attendees will gain 60 days of on-demand access following the live event.
Register now to secure access to the ASGCT 28th Annual Meeting and be part of the driving force behind cell and gene therapy. Visit annualmeeting.asgct.org for more details and updates.